Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has announced a favorable study design update for its pivotal Phase 3 SENTRY trial, which is evaluating selinexor in patients with myelofibrosis who are naive to JAK inhibitor treatment. The company hosted a conference call and audio webcast on October 31, 2024, to discuss the update with leading myelofibrosis experts.
The SENTRY trial is designed to assess the efficacy and safety of selinexor, an oral exportin 1 (XPO1) inhibitor, in myelofibrosis patients who have not previously received JAK inhibitor therapy. This patient population represents a significant unmet medical need, as many individuals either do not respond to or are ineligible for existing JAK inhibitor treatments.
Key Opinion Leader Involvement
The conference call featured insights from prominent key opinion leaders in the field of myelofibrosis, including Dr. Raajit Rampal, Director of the Center for Hematologic Malignancies and Director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, and Dr. John Mascarenhas, principal investigator of the Phase 3 SENTRY trial, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders. Their participation underscores the importance of the SENTRY trial and the potential of selinexor to address the unmet needs in this patient population.
Selinexor: An XPO1 Inhibitor
Selinexor, marketed as XPOVIO in the U.S. and NEXPOVIO in Europe and the UK, is Karyopharm's lead compound and a first-in-class, oral exportin 1 (XPO1) inhibitor. It is already approved in the U.S. for several oncology indications and has received regulatory approvals in various other countries. Karyopharm is focusing its pipeline on indications in multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
